Sompharmaceuticals
Financials
Estimates*
EUR | 2015 | 2016 | 2017 | 2018 |
---|---|---|---|---|
Revenues | 4.6m | 4.7m | 4.3m | 4.4m |
% growth | - | 1 % | (8 %) | 4 % |
Date | Investors | Amount | Round |
---|---|---|---|
CHF100k | Seed | ||
N/A | CHF750k | Series A | |
N/A | Acquisition | ||
Total Funding | $779k |
Related Content
Recent News about Sompharmaceuticals
EditAmryt Pharma Plc is dedicated to developing and commercializing breakthrough medicines aimed at treating rare and ultra-rare orphan diseases, which are conditions that affect a very small percentage of the population and often have limited treatment options. The company serves healthcare professionals and patients who face some of the most challenging medical conditions, providing them with innovative solutions that can significantly improve quality of life. Operating in the global pharmaceutical market, Amryt Pharma's business model focuses on research and development, strategic partnerships, and commercialization of its proprietary treatments. The company generates revenue through the sale of its specialized medicines and through collaborations with other pharmaceutical entities. Amryt Pharma's success is driven by its commitment to addressing high unmet medical needs and its ability to quickly and responsibly bring new treatments to market. The company prides itself on its nimble and creative approach to deal-making, ensuring mutual benefits for all parties involved. Keywords: rare diseases, ultra-rare diseases, orphan drugs, innovative treatments, healthcare professionals, patient care, pharmaceutical partnerships, global market, research and development, commercialization.